Silva Viviane da C, Teixeira Raquel L de F, do Livramento Rebecca E E N O, Lopes Márcia Q P, Leal-Calvo Thyago, Filho José E, Luduvice Márcia B V, Rodrigues Lilian de C, Bossois Marcello, Schlinkert Patricia F, Neves Anderson S, Suffys Philip N, Lapa E Silva José Roberto, Santos Adalberto R
Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, RJ, Brazil.
Leprosy Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, RJ, Brazil.
Curr Issues Mol Biol. 2024 Jul 4;46(7):6951-6959. doi: 10.3390/cimb46070414.
Asthma is a chronic inflammatory respiratory condition, characterized by variable airflow limitation, leading to clinical symptoms such as dyspnea and chest tightness. These symptoms result from an underlying inflammatory process. The β2 agonists are bronchodilators prescribed for the relief of the disease. Nevertheless, their efficacy exhibits substantial interindividual variability. Currently, there is widespread recognition of the association between specific genetic variants, predominantly located within the and genes and their efficacy. This association, usually represented by the presence of non-synonymous single nucleotide polymorphisms (SNPs) have a strong impact in the protein functionality. The prevalence of these mutations varies based on the ethnic composition of the population and thus understanding the profiles of variability in different populations would contribute significantly to standardizing the use of these medications. In this study, we conducted a sequence-based genotyping of the relevant SNPs within the and genes in patients undergoing treatment with bronchodilators and/or corticosteroids at two healthcare facilities in the state of Rio de Janeiro, Brazil. We investigated the presence of c.46A>G, c.79C>G, c.252G>A, and c.491C>T SNPs within the , and c.1320018 A>G within the . Our results were in line with existing literature data with both for individuals in Brazil and Latin American.
哮喘是一种慢性炎性呼吸系统疾病,其特征为气流受限可变,可导致诸如呼吸困难和胸闷等临床症状。这些症状源于潜在的炎症过程。β2激动剂是用于缓解该疾病的支气管扩张剂。然而,它们的疗效存在显著的个体间差异。目前,人们普遍认识到特定基因变异(主要位于 和 基因内)与其疗效之间的关联。这种关联通常由非同义单核苷酸多态性(SNP)的存在来表示,对蛋白质功能有强烈影响。这些突变的患病率因人群的种族构成而异,因此了解不同人群的变异情况将对规范这些药物的使用有很大帮助。在本研究中,我们对巴西里约热内卢州两家医疗机构中正在接受支气管扩张剂和/或皮质类固醇治疗的患者的 和 基因内相关SNP进行了基于序列的基因分型。我们调查了 基因内c.46A>G、c.79C>G、c.252G>A和c.491C>T SNP的存在情况,以及 基因内c.1320018 A>G的存在情况。我们的结果与巴西和拉丁美洲个体的现有文献数据一致。